Conversion of Tislelizumab Combined With Chemotherapy in Unresectable Esophageal Squamous Cell Carcinoma
Status:
Recruiting
Trial end date:
2025-06-30
Target enrollment:
Participant gender:
Summary
Whether the introduction of immunotherapy can transform unresectable esophageal cancer into
resectable, or even achieve R0 surgical resection, has not been reported yet. We plan to
conduct a prospective, single-center, single-arm phase II clinical study of the safety and
efficacy of tislelizumab combined with chemotherapy in the treatment of unresectable
esophageal squamous cell carcinoma.
Phase:
Phase 2
Details
Lead Sponsor:
Tianjin Medical University Cancer Institute and Hospital